The Myelofibrosis Risk Assessment Tool grew out of the work of the MS3T, the MPN Stem Cell Transplantation Timing Taskforce
For MF patients with high risk or progressing myelofibrosis, the only cure is a stem cell transplant. The timing of the SCT is critical and too often MF patients delayed the procedure until the onset of blast phase of progression to Acute Myeloid Leukemia where the outcomes were unfavorable. Internationally renowned hematologists, transplanters, pathologists, teamed up with MPN patient advocates in Taskforce focused on this issue.
The conclusion: A simple, free, graphically striking on-line tool that incorporated current findings on myelofibrosis assessment could help reduce the toll resulting from delay of stem cell transplant.
The MS3T reviewed the clinically validated DIPSS and DIPSS+ scales that measured myelofibrosis risk levels and consulted on the construction of the Stem Cell Transplant Timing Tool (SSTT, http://www.mpntransplant.com/)
The same scoring scales and risk assessment that applied to SCT timing is applicable to prognostic application in myelofibrosis as an aid to determining levels of treatment, from Watch & Wait or low level intervention in low risk MF to SCT or entry to clinical trial for higher risk levels. Adapting the SCT tool to the general MF population was a natural extension of the Taskforce’s work.
The addition of mutational burden added an extra dimension to the tool. The new tool, renamed MAGIC (Myelofibrosis Assessment Graphic Internet Calculator) simply lists and totals mutations. The mutation analysis section is integrally linked to “Notes on MPN Mutations,”here and in the MPN Quarterly Journal The Notes provide more detail on the most common MPN mutations and a general background on the MPN mutational landscape..
The MPN Research Foundation sponsored both the SSTT and the M/RAT as part of its myelofibrosis and SCT education and patient support programming.
The MPN Research Foundation launch announcement to media is here.
Dr. Claire Harrison
Professor and Clinical Director, Guy’s and St. Thomas’ Hospital, London
Dr. Ruben Mesa
Director, Mays Cancer Center of UT Health San Antonio MD Anderson Cancer Center
Dr. Richard T. Silver
Professor of Medicine, Weill-Cornell
Richard T Silver MD Myeloproliferative Neoplasms Center
Dr. Srdan Verstovsek
Department of Leukemia, UT MD Anderson Cancer Center, Houston
Dr. Koen Van Besien
Director, SCT program, Weill-Cornell
Dr. Nicolaus Kroeger
Medical Director, SCT, University Hospital, Hamburg
Dr. Jeanne Palmer
Medical Director, BMT, Mayo Clinic, Phoenix
Dr. Uday Popat
Professor Dept of SCT, MD Anderson
Dr. Attilio Orazi
Professor of Pathology, Director of Hematopathology, Weill-Cornell
Dr. Wael Saber
Scientific Director, CIBMTR, Associate Professor
Medical College of Wisconsin
MPN SCT Patients
MPN Patient Advocates
MPN Advocacy and Education, CEO
President and Founder, Genny’s Hope Foundation
Barbara Van Husen
CEO, MPN Research Foundation
Director, MPN Research Foundation
Editor & Publisher, MPN Quarterly Journal/MPNforum
The MPN Research Foundation
Special thanks to the MS3t Taskforce and to Ed Bartholemy, Diane Blackstock, Zeta Charania, John Crispino, David Denny, Brandon Goetz, Jacob Grinfeld, Claire Harrison, Ruben Mesa, Pam Murphy, Jerry Spivak and William Vainchenker. Dedicated to the memory of Robert Rosen.